Aladar Szalay Sells 6,403 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 6,403 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $3.25, for a total value of $20,809.75. Following the completion of the sale, the insider now owns 1,249,327 shares in the company, valued at $4,060,312.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The stock was sold at an average price of $3.30, for a total value of $109,101.30.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Trading Up 10.1 %

Shares of NASDAQ:GNLX opened at $3.83 on Friday. Genelux Co. has a 12 month low of $3.06 and a 12 month high of $40.98. The firm’s 50-day moving average is $5.34 and its 200 day moving average is $10.26.

Genelux (NASDAQ:GNLX) last released its earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Sell-side analysts anticipate that Genelux Co. will post -0.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GNLX has been the subject of several recent research reports. HC Wainwright dropped their price target on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Benchmark reiterated a “speculative buy” rating and issued a $30.00 target price on shares of Genelux in a report on Wednesday, April 3rd.

Institutional Trading of Genelux

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Woodward Diversified Capital LLC boosted its stake in shares of Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares during the period. LifeSteps Financial Inc. raised its stake in shares of Genelux by 26.6% during the first quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company’s stock valued at $285,000 after acquiring an additional 9,301 shares in the last quarter. Clarity Capital Partners LLC bought a new stake in shares of Genelux during the fourth quarter valued at approximately $364,000. Tower Research Capital LLC TRC boosted its holdings in shares of Genelux by 216.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after purchasing an additional 2,021 shares during the period. Finally, Apollon Wealth Management LLC bought a new position in Genelux in the fourth quarter worth approximately $196,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.